These are the monoclonal antibody drugs sotrovimab (by GSK and Vir Biotechnology) and casirivimab-imdevimab (“cocktail” by Regeneron and Roche).
The World Health Organization (WHO) is issuing a “strong recommendation” against two antibody treatments against Covid-19, as it now considers them ineffective, replacing its previous recommendation for their use. These are the monoclonal antibody drugs sotrovimab (by GSK and Vir Biotechnology) and casirivimab-imdevimab (“cocktail” by Regeneron and Roche).
The group of international WHO experts (WHO Guideline Development Group) made the relevant publication in the British medical journal “British Medical Journal” (BMJ). The new negative recommendation came after laboratory studies showed that the drugs in question are unlikely to be effective against new variants of the coronavirus, especially Omicron and its sub-variants.
See the study here
In the same updated guideline the WHO committee recommends the conditional use of the antiviral drug remdesivir (from Gilead) in patients with severe Covid-19, but not in those in critical condition. The new recommendation was based on the results of five clinical studies in a total of 7,643 patients, which showed 13 fewer deaths per 1,000 patients with severe Covid-19 among those taking remdesivir, but 34 more deaths per 1,000 patients with critical Covid-19.
The WHO also advises that three anti-arthritis drugs (tocilizumab or sarilumab and baricitinib) can now be combined, in addition to corticosteroids, in patients with severe or critical Covid-19. Finally, he opposes the use of ivermectin and hydroxychloroquine in patients with Covid-19, regardless of how seriously ill they are.
RES-EMP
Read the News today and get the latest news.
Follow Skai.gr on Google News and be the first to know all the news.
As a seasoned news journalist, I bring a wealth of experience to the field. I’ve worked with world-renowned news organizations, honing my skills as a writer and reporter. Currently, I write for the sports section at News Bulletin 247, where I bring a unique perspective to every story.
